Amicus Therapeutics Announces Additional Positive Phase 3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011

Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR)

Additional GL-3 Data Further Validate Assay for Identifying Patients with Amenable Mutations

CRANBURY, N.J., and SAN DIEGO, Oct. 19, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data from a Phase 3 study ( Study 011 ) of the oral small molecule chaperone migalastat HCl ("migalastat") in Fabry disease patients with amenable mutations. In a poster at the American Society of Human Genetics (ASHG) Annual Meeting , Daniel G. Bichet, M.D., M.Sc., Professor, Department of Physiology, University of Montreal, presented results from patients in Study 011 including those who continued on migalastat in an open-label extension ( Study 041 ).

Assessment of kidney function by various measures of glomerular filtration rate (GFR) for patients receiving migalastat in Study 011 for at least 18 months and continuing migalastat treatment in Study 041 showed continued stability of kidney function for an average of 32 months. Decline in kidney function is a key cause of morbidity and mortality in patients with Fabry disease. Measured (iohexol) GFR (mGFR) showed stability over 18-24 months in Study 011 but was not collected in Study 041; mGFR was previously reported with topline Study 011 results .

  Mean Annualized Change in GFR (ml/min/m2/yr) (SEM)
Over an Average of 32 Months with Migalastat in 011 and 041
Estimated GFR (eGFR) (CKD-EPI) (n=41) -0.20 (0.60)
eGFR (MDRD) (n=41) +0.63 (0.08)

Stratifying patients for gender and baseline proteinuria demonstrated that patients treated with migalastat experienced less decline in kidney function than untreated patients from a previously published natural history study 1 .

Dr. Daniel Bichet, Full Professor and Section Head, Renal Function & Transport Physiology, University of Montreal, said, "Baseline proteinuria levels are among the most predictive indicators of disease prognosis and kidney function decline in Fabry patients. The data presented today show that when comparing patients with similar levels of proteinuria, patients treated with migalastat are more stable in their kidney function versus untreated patients. These results are very encouraging for migalastat as a treatment for Fabry patients with amenable mutations." 

Data from a subgroup analysis comparing the change in GL-3 substrate levels between amenable patients and non-amenable patients based on the GLP HEK cell assay provided additional validation of the sensitivity of the GLP HEK assay for identifying patients who will respond to migalastat monotherapy. Overall, patients with amenable mutations had declining levels of GL-3 when treated for six months with migalastat. In contrast, patients with non-amenable mutations had no change or increasing levels of GL-3 after six months of migalastat treatment.

"We are pleased to present these additional Phase 3 results in a scientific forum. With 32 months of data, Fabry patients treated with migalastat exhibit long-term stability in their kidney function. These results contrast with the decline in kidney function reported in natural history studies. Decline in kidney function is one of the primary causes of morbidity and mortality in Fabry patients," stated Dr. Jay A. Barth, Chief Medical Officer of Amicus Therapeutics, Inc. "The additional data on substrate reduction show that we can accurately identify patients who may benefit from migalastat. We look forward to meeting with regulatory agencies starting this quarter as we work to make migalastat available for all amenable Fabry patients as quickly as possible."

About GLP HEK-Amenable Mutations

Amenable mutations are defined as having an absolute increase of 3% of wild type alpha-Gal A enzyme activity and a relative increase of 20% when exposed to migalastat in a cell-based in vitro assay. All patients enrolled in Study 011 had amenable mutations in the clinical trial HEK assay available at study initiation ("clinical trial assay"). Following the completion of enrollment, a GLP HEK assay was developed with a third party to measure the criteria for amenability with more quality control and rigor. However, approximately 10% of mutations in the HEK database switched categorization between "amenable" and "non-amenable" when moving from the clinical trial assay to the GLP HEK assay. Therefore, there were changes in categorization from amenable to non-amenable in 17 patients in Study 011. 

Overall based on results from mutations tested in the GLP HEK assay, Amicus estimates that approximately 30% to 50% of the Fabry population has mutations that are amenable to migalastat.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD ) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.

1 Schiffmann et al., Nephrol Dial Transplant (2009) 

Forward-Looking Statements

This press release contains, and the accompanying conference call will contain, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products and the projected cash position for the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "potential," "plan," "targets," "likely," "may," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD–G

Investors/Media: Chip Baird (609) 662-2063 Media: Dan Budwick (973) 271-6085

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

ParagonX Holdings: Update on Company Transformation Plans

Updated Category News Views 146

ParagonX Holdings Shareholder Update ParagonX Holdings, Inc. (OTC:CAVR) recently shared insightful information regarding its transformation and strategic direction. The company is under the management of Caprino Management, LLC, which is actively assessing acquisition opportunities to bolster its growth. Divestitures and Debt Restructuring A significant step taken by...

Continue Reading
Applaud Receives Prestigious AI Award for Transforming HR

Updated Category News Views 300

Applaud Triumphs with Prestigious AI Award Applaud, a leading innovator in HR technology, has achieved significant recognition in the tech industry. The company’s generative-AI HR platform was awarded the flagship AI Award at a major international event. Applaud was selected among several finalists, showcasing its commitment to providing measurable value to employees...

Continue Reading
Empowering Stories: A Mother's Journey to a New Start

Updated Category News Views 257

Empowering Stories: A Mother's Journey to a New Start Anita's story is one of resilience. Faced with overwhelming challenges in her early life, she fought tirelessly to change her circumstances. Growing up without a family, she was married at a tender age to an older man, and for years, she juggled the responsibilities of motherhood while tending to her husband’s...

Continue Reading
First Capital REIT Declares Monthly Distribution for Investors

Updated Category News Views 176

First Capital REIT Announces Distribution for October 2025 First Capital REIT announces its cash distribution for October 2025, setting a notable precedent for its unitholders. The company has declared a distribution of $0.074167 per REIT unit, which translates to an annualized payout of $0.89 per unit. The payment is scheduled for November 17, 2025, to unitholders...

Continue Reading
Sidus Space and Other Major Stocks Experience Declines

Updated Category News Views 166

Stock Market Dynamics: Sidus Space and Others The U.S. stock market is seeing some fluctuations as futures showed little movement earlier today. Among these movements, Nasdaq 100 futures gently slipped by about 0.01%. In the midst of this, shares of Sidus Space, Inc. (NASDAQ: SIDU) are particularly noteworthy. Sidus Space's Price Adjustment Sidus Space recently made...

Continue Reading